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Abstracts
 
BACKGROUND:
 
 Selection of biological versus mechani-
cal heart valve replacement entails tradeoffs in the risk and
expected cost of post-operative bleeding, embolic events
and reoperation. Additionally, the risk of these events var-
ies by age at implant.
OBJECTIVE: To identify the direct medical costs to the
NHS of biological and mechanical valve replacement in
younger versus older patients.
METHODS: A Markov decision-analytic model was con-
structed to identify the cumulative lifetime costs of valve
replacement and related events in a simulated cohort of
10,000 patients followed from valve implantation until
death. Events included bleeding, embolism, endocarditis,
structural valve deterioration, reoperation and death. Event
rates were modeled using linear, and non-linear statistical
hazard functions based on clinical series reported in the
literature. Medical resource use related to events was es-
timated based on clinical expert opinion. Costs were as-
signed to each event using standard lists of NHS costs.
RESULTS: For aortic valve replacement, the expected life-
time costs were £6,812 (biological) and £8,873 (mechani-
cal) for persons aged 60, versus £6,281 (biological) and
£8,137 (mechanical) for persons aged 70 at implant, re-
spectively. In the mitral position, costs were £6,968 (biolog-
ical) and £8,760 (mechanical) versus £6,299 (biological)
and £7,989 (mechanical) in persons aged 60 versus 70 at
implant respectively. Results were most sensitive to bleed-
ing, embolic and reoperation event rates, but less sensitive
to the cost per event.
CONCLUSION: The expected lifetime cost of biologic
valve replacement was lower than mechanical valve re-
placement for both age groups and valve positions. This
suggests the economic impact of anticoagulation therapy,
bleeding and embolic events, which occur at higher rates in
the mechanical valve, is greater than the economic impact
of structural valve deterioration leading to reoperation,
which is greater in the biological valve.
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COST-EFFECTIVENESS OF STATINS: MOVING 
BEYOND THE PRIMARY AND SECONDARY 
PREVENTION DISTINCTION
 
Caro J, for the CORE Study Group
Caro Research Boston, MA, USA
BACKGROUND: Economic analyses of cardiovascular dis-
ease (CVD) prevention with statins have generated contro-
versy on the most efficient allocation of health care funds:
primary prevention, secondary or both? Previous analyses
have focused on one setting or the other. Comparing these
two oversimplifies the task of allocating health care re-
sources and may lead to unjustified decisions concerning
“appropriate” statin use. Instead, an integrated view across
the continuum of risk is required.
METHODS: An economic model of CVD prevention with
pravastatin—Continuum of Risk Evaluation (CORE)—
based on West of Scotland Coronary Prevention Study (pri-
mary prevention) and Cholesterol and Recurrent Events
(secondary prevention) study data is detailed. The model
simulates 10,000 individuals at various stages of CVD
(prior manifestation of CVD through multiple events). All
events are tallied in monthly cycles with costs and life ex-
pectancy implications applied appropriately.
ANALYSES: Analyses were completed for various popula-
tions and treatment strategies to help determine the most
cost-effective scenarios. For the purpose of these analyses,
populations were described in terms of the proportion of
individuals at various disease stages at the start of follow-
up. Treatment strategies were defined on the basis of the
risk cut-off at which treatment is initiated for individuals
without pre-existing disease. Analyses were conducted fol-
lowing the NCEP and Canadian treatment guidelines.
CONCLUSION: An integrated approach to prevention of
CVD is an area that has not been explored in term of its
economic impact. CORE permits realistic analysis of pol-
icy decisions which involve the entire continuum of risk
rather then isolated consideration of specific, but arbi-
trary, “stages” of disease.
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ASSOCIATED WITH TREATMENT OF 
CARDIOVASCULAR DISEASES IN PATIENTS 
WITH CLINICAL CORONARY ARTERY DISEASE
Chen G, Byington R, Moran M
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NC, USA
OBJECTIVE: To examine whether amlodipine can reduce
hospitalization associated with treatment of cardiovascu-
lar disease (CVD) in patients with angiographic evidence
of coronary artery disease. Amlodipine is a long acting cal-
cium channel antagonist that has been proven to be effec-
tive in treating cardiovascular diseases.
METHOD: We used clinical data derived from the Pro-
spective Randomized Evaluation of Vascular Effects of
Norvasc Trial (PREVENT). PREVENT was a 3-year, ran-
domized, masked, placebo-controlled, multicenter, clinical
trial originally designed to test the antiatherogenic effect of
the calcium channel blocker amlodipine in 825 patients
with coronary artery disease (417 patients for amlodipine
and 408 patients for placebo). The outcome measures were
clinical CVD events associated with hospital care which in-
cluded congestive heart failure (CHF), myocardial infarc-
tion (MI), stroke, angina, coronary artery bypass graft
(CABG), percutaneous coronary angioplasty (PTCA), stents,
athrectomy, valve replacement, and catheterization.
RESULTS: Overall, the net number of hospitalization asso-
ciated with CVD averted was 27.9 per 100 patients
(38.51% reduction) in the amlodipine patient group over
three years of the study. Comparing with the placebo group,
the treatment group had fewer hospitalizations related to
PTCA (11.75 per 100 patients, 52.69% reduction),
CABG (3.03, 42.62% reduction), stent (2.02, 41.22%
reduction), angina (9.27, 31.52% reduction), and CHF
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(
 

 
2.46, 91.11% reduction). There were no significant im-
pacts on hospital utilization related to stroke (
 

 
0.03 per
100 patients), valve replacement (0.48) and fatal MI (0.13).
CONCLUSION: In this study, amlodipine is found to be
an effective agent in reducing hospital utilization related to
CVD, especially CHF, PTCA, CABG, stent, and angina, in
patients with clinical coronary artery disease relative to the
placebo. Further analysis will examine whether amlodipine
can reduce hospital care costs associated with CVD.
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Discontinuation of drug use constitutes a major barrier to
adequate control of high blood pressure. Although various
factors may be associated with discontinuation of treat-
ment, so far, very few causal associations have been studied.
OBJECTIVES: To examine the effect of an array of poten-
tial predisposing, enabling and reinforcing factors on dis-
continuation of initial antihypertensive medication.
METHODS: We conducted a prospective cohort study
through a network of 173 pharmacies across Canada who
identified individuals starting a new antihypertensive medi-
cation as a monotherapy. We excluded pregnant women,
individuals who were taking other antihypertensive medi-
cations at the same time, and those who took medications
for chronic heart failure, or angina. We interviewed sub-
jects by telephone four times over a 36 month period. We
analyzed data using a Cox’s proportional hazard model.
RESULTS: Out of 682 eligible subjects, 43% had discon-
tinued their initial medication at the end of the observation
period. Individuals more likely to discontinue their initial
medication were those who perceived side effects with the
initial medication (Adjusted Hazard Ratio (AHR)  1.91;
95% Confidence interval (CI)  1.47–2.48) and those who
believed the antihypertensive medication had no effect
(AHR  1.33; 95% CI  1.03–1.72). Insurance coverage
for antihypertensive medication had a protective effect
(AHR  0.74; 95% CI  0.55–0.99).
CONCLUSIONS: Persistence with newly prescribed medi-
cations could be improved by selecting antihypertensive
medications with fewer side effects, by changing misleading
perceptions of patients about their treatment, and by re-
moving economical barriers.
ECONOMIC & OUTCOMES STUDY RESULTS OF 
DISEASES OF THE CENTRAL NERVOUS SYSTEM
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COSTS OF DEMENTIA IN GERMANY—AN 
ANALYSIS OF 7490 HEALTH INSURANCE FILES
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OBJECTIVE: The economic burden of dementia combined
with financial crisis in public health systems makes study-
ing costs of dementia very important. In Germany only one
“bottom-up”-study (150 patient records) of office based
physicians demonstrated the burden of dementia disease.
Our study is the first one in Germany using social health in-
surance data to demonstrate the costs of dementia for the
social health insurance.
METHOD: Direct costs incurred in the outpatient sector
for diagnosis and treatment of dementia were calculated by
means of analysis of health insurance data from the statu-
tory health insurance fund (AOK) of the region Dresden/
Riesa. At a defined date (1st July 1993) a random sample of
7490 insured persons were selected from the AOK master
file. The following data was covered: personal data, pre-
scription sheets, claim forms with diagnosis, diagnostic and
therapeutic procedures. Information about hospital treat-
ment was available from 1st and 2nd quarter of 1994. Plain-
text diagnosis was transferred into ICD 10 code. Demented
patients were identified by ICD items F00 to F09 and I60
to I69. A control group of non-demented patients identical
to the dementia group in terms of age and sex was selected
from the AOK sample using the matched pair method (two
controls for each case).
RESULTS: 327 of 7490 insured persons were diagnosed as
demented (one-year prevalence: 4.4%). Diagnostic proce-
dures and non-pharmacological care interventions were or-
dered significantly more often in cases than in controls.
79.2% cases vs. 44.2% controls were prescribed at least one
of the drugs associated with dementia. Office based phy-
sicians are more often visited by demented than by non-
demented patients (23 vs. 90 visits per year). Hospitaliza-
tion rate in cases was higher than in controls (11,0 vs.
5,1%). This data allowed calculation of the total direct
costs covered by social health insurance in one year for a de-
mented patient: EUR 4080,64 (diagnostics EUR 1128,52;
medication EUR 1906,94; non-pharmacological care inter-
vention EUR 107,18; hospital EUR 977,13). Compared
with controls the following attributed costs per case per
year were found: Total EUR 823,80 (diagnostics EUR
247,22; medication EUR 387,65; non-pharmacological care
interventions EUR 93,30; hospital EUR104,64).
CONCLUSION: The data indicated, that demented pa-
tients are not treated properly. Recommendations for ratio-
nal treatment of dementia should be implemented in the
outpatient setting.
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